PT3715367T - Proteína de fusão compreendendo proteína il-2 e proteína cd80, e sua utilização - Google Patents
Proteína de fusão compreendendo proteína il-2 e proteína cd80, e sua utilizaçãoInfo
- Publication number
- PT3715367T PT3715367T PT198624496T PT19862449T PT3715367T PT 3715367 T PT3715367 T PT 3715367T PT 198624496 T PT198624496 T PT 198624496T PT 19862449 T PT19862449 T PT 19862449T PT 3715367 T PT3715367 T PT 3715367T
- Authority
- PT
- Portugal
- Prior art keywords
- protein
- fusion
- fusion protein
- Prior art date
Links
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 title 1
- 108010002350 Interleukin-2 Proteins 0.000 title 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20180110698 | 2018-09-17 | ||
| KR20190001867 | 2019-01-07 | ||
| US201962832013P | 2019-04-10 | 2019-04-10 | |
| KR20190053436 | 2019-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3715367T true PT3715367T (pt) | 2024-07-25 |
Family
ID=69887592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT198624496T PT3715367T (pt) | 2018-09-17 | 2019-09-16 | Proteína de fusão compreendendo proteína il-2 e proteína cd80, e sua utilização |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US11492384B2 (https=) |
| EP (2) | EP3715367B1 (https=) |
| JP (2) | JP7085644B2 (https=) |
| KR (2) | KR102201086B1 (https=) |
| CN (2) | CN111971295B (https=) |
| AU (1) | AU2019343850B2 (https=) |
| CA (1) | CA3086486A1 (https=) |
| CL (1) | CL2020001872A1 (https=) |
| DK (1) | DK3715367T3 (https=) |
| ES (1) | ES2985387T3 (https=) |
| FI (1) | FI3715367T3 (https=) |
| HU (1) | HUE068059T2 (https=) |
| IL (1) | IL275592B (https=) |
| MX (1) | MX2020007072A (https=) |
| PE (1) | PE20201418A1 (https=) |
| PH (1) | PH12020551026A1 (https=) |
| PL (1) | PL3715367T3 (https=) |
| PT (1) | PT3715367T (https=) |
| SG (1) | SG11202005873QA (https=) |
| TW (2) | TWI755630B (https=) |
| WO (1) | WO2020060122A1 (https=) |
| ZA (1) | ZA202003645B (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2769282C2 (ru) * | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| US11492384B2 (en) * | 2018-09-17 | 2022-11-08 | Gi Innovation, Inc. | Fusion protein comprising IL-2 protein and CD80 protein, and use thereof |
| KR102351020B1 (ko) * | 2019-11-20 | 2022-01-14 | 주식회사 지아이셀 | 자연살해세포 배양용 조성물 및 이를 이용한 자연살해세포 제조방법 |
| AU2020389422B2 (en) * | 2019-11-20 | 2024-08-08 | Gi Cell, Inc. | Medium composition for culturing T cells and method for culturing T cells using same |
| US20230014358A1 (en) * | 2019-11-27 | 2023-01-19 | Gi Cell, Inc. | Composition for anticancer treatment, comprising nk cells and fusion protein which comprises il-2 protein and cd80 protein |
| IL292935A (en) * | 2019-11-27 | 2022-07-01 | Gi Cell Inc | A compound for anti-cancer treatment, which includes nk cells and a fusion protein including il-2 protein and cd80 protein |
| JP7697959B2 (ja) | 2020-03-18 | 2025-06-24 | ジーアイ イノベーション， インコーポレイテッド | Ｉｌ－２タンパク質とｃｄ８０タンパク質を含む融合タンパク質製剤 |
| KR102440962B1 (ko) * | 2020-03-18 | 2022-09-07 | ㈜지아이이노베이션 | Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 항암제를 포함하는 암 치료용 약학 조성물 |
| KR20210117208A (ko) * | 2020-03-18 | 2021-09-28 | (주)지아이이노베이션 | Il-2 단백질 및 cd80 단백질 단편 또는 이의 변이체를 포함하는 융합단백질 및 이의 용도 |
| CN118271419A (zh) * | 2020-03-31 | 2024-07-02 | 韩美药品株式会社 | 新型免疫刺激il-2类似物 |
| CN115943165A (zh) * | 2020-05-25 | 2023-04-07 | 北京比洋生物技术有限公司 | Fc-CD80融合蛋白和其缀合物以及它们的用途 |
| KR102373965B1 (ko) * | 2020-06-05 | 2022-03-15 | (주)지아이이노베이션 | Ｉｌ-２ 단백질 및 ｃｄ８０ 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물 |
| EP4174088A4 (en) * | 2020-06-30 | 2024-01-24 | GI Innovation, Inc. | FUSION PROTEIN COMPRISING AN ANTI-LAG-3 AND IL-2 ANTIBODY AND USE THEREOF |
| US20230235005A1 (en) * | 2020-07-02 | 2023-07-27 | Inhibrx, Inc. | Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof |
| WO2022045849A1 (ko) * | 2020-08-31 | 2022-03-03 | 주식회사 지아이셀 | Il15 단백질, il15 수용체 알파 단백질, fc 도메인 및 il2 단백질을 포함하는 융합단백질 및 이의 용도 |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| JP2023552810A (ja) * | 2020-12-08 | 2023-12-19 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | 抗ｅｇｆｒキメラ抗原受容体 |
| IL305758A (en) * | 2021-03-10 | 2023-11-01 | Immunowake Inc | Immunomodulatory compounds and their uses |
| WO2022057696A2 (zh) * | 2021-09-08 | 2022-03-24 | 中南大学湘雅医院 | 一种重组蛋白的编码序列、重组蛋白及其单克隆抗体的制备方法 |
| KR20230168273A (ko) * | 2022-06-03 | 2023-12-13 | (주)지아이이노베이션 | 항-tigit 항체를 포함하는 이중 특이적 항체 및 이의 용도 |
| WO2023249425A1 (ko) * | 2022-06-22 | 2023-12-28 | ㈜지아이이노베이션 | 항-cd73 항체 및 il-2를 포함하는 융합단백질 및 이의 용도 |
| CN119997963A (zh) * | 2022-09-20 | 2025-05-13 | 南韩商Gi生物群系公司 | 植物乳杆菌菌株的联合疗法及利用该菌株的癌症治疗方法 |
| JP2025534272A (ja) * | 2022-09-20 | 2025-10-15 | ジーアイ バイオム インコーポレイテッド | ラクトバチルス・プランタルム菌株の併用療法及びそれを用いた癌の治療方法 |
| CN115850436B (zh) * | 2022-10-14 | 2026-02-03 | 海徕科(北京)生物技术有限公司 | 白介素2突变体及其应用 |
| WO2025063755A1 (ko) * | 2023-09-20 | 2025-03-27 | 주식회사 에스엘바이젠 | 항암 dna 백신 및 면역반응-증진용 융합단백질을 포함하는 신규 암 치료제 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA842025B (en) * | 1983-03-21 | 1984-11-28 | Hoffmann La Roche | Interleuken-2 |
| CN86104525A (zh) * | 1985-07-31 | 1987-02-25 | 武田药品工业株式会社 | 人类白细胞介素-2的分析方法和试剂 |
| US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
| US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| DZ2788A1 (fr) * | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| GB9810999D0 (en) | 1998-05-21 | 1998-07-22 | Goken Joop | Materials and methods relating to the expression of genes |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| WO2003015697A2 (en) * | 2001-08-13 | 2003-02-27 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
| DK1454138T3 (da) | 2001-12-04 | 2012-02-13 | Merck Patent Gmbh | Immunocytokiner med moduleret selektivitet |
| CU23229A1 (es) | 2002-05-10 | 2007-09-26 | Ct Ingenieria Genetica Biotech | ANTAGONISTA QUIMéRICO ANTH1 |
| US20060234205A1 (en) * | 2004-03-05 | 2006-10-19 | Chiron Corporation | In vitro test system for predicting patient tolerability of therapeutic agents |
| EP2402754B2 (en) * | 2006-03-06 | 2023-07-26 | Amunix Operating Inc. | Unstructured recombinant polymers and uses thereof |
| AU2007271398B2 (en) * | 2006-07-06 | 2013-06-20 | Merck Patent Gmbh | Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses |
| JP2010536341A (ja) * | 2007-08-15 | 2010-12-02 | アムニクス， インコーポレイテッド | 生物学的に活性なポリペプチドの特性を改変するための組成物および方法 |
| CU23923B1 (es) * | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
| SG192673A1 (en) * | 2011-02-10 | 2013-09-30 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| US8956619B2 (en) * | 2011-10-25 | 2015-02-17 | University Of Maryland, Baltimore County | Soluble CD80 as a therapeutic to reverse immune supression in cancer patients |
| US20140377253A1 (en) * | 2013-03-15 | 2014-12-25 | Abbvie Biotherapeutics Inc. | Fc variants |
| DK3186283T3 (da) | 2014-08-29 | 2020-03-02 | Hoffmann La Roche | Kombinationsbehandling med tumormålrettede IL-2- immuncytokinervarianter og antistoffer mod humant PD-L1 |
| US10273281B2 (en) * | 2015-11-02 | 2019-04-30 | Five Prime Therapeutics, Inc. | CD80 extracellular domain polypeptides and their use in cancer treatment |
| JP7422480B2 (ja) * | 2016-05-04 | 2024-01-26 | アムジエン・インコーポレーテツド | 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質 |
| US9567399B1 (en) * | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| RU2769282C2 (ru) * | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| MY201482A (en) | 2017-04-03 | 2024-02-26 | Hoffmann La Roche | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 |
| US11492384B2 (en) | 2018-09-17 | 2022-11-08 | Gi Innovation, Inc. | Fusion protein comprising IL-2 protein and CD80 protein, and use thereof |
-
2019
- 2019-09-16 US US16/959,312 patent/US11492384B2/en active Active
- 2019-09-16 EP EP19862449.6A patent/EP3715367B1/en active Active
- 2019-09-16 FI FIEP19862449.6T patent/FI3715367T3/fi active
- 2019-09-16 JP JP2020562067A patent/JP7085644B2/ja active Active
- 2019-09-16 WO PCT/KR2019/011928 patent/WO2020060122A1/ko not_active Ceased
- 2019-09-16 CN CN201980025699.8A patent/CN111971295B/zh active Active
- 2019-09-16 EP EP24175556.0A patent/EP4403635A3/en active Pending
- 2019-09-16 SG SG11202005873QA patent/SG11202005873QA/en unknown
- 2019-09-16 AU AU2019343850A patent/AU2019343850B2/en active Active
- 2019-09-16 KR KR1020190113659A patent/KR102201086B1/ko active Active
- 2019-09-16 CN CN202410942368.3A patent/CN118725141A/zh active Pending
- 2019-09-16 CA CA3086486A patent/CA3086486A1/en active Pending
- 2019-09-16 HU HUE19862449A patent/HUE068059T2/hu unknown
- 2019-09-16 PE PE2020000980A patent/PE20201418A1/es unknown
- 2019-09-16 PL PL19862449.6T patent/PL3715367T3/pl unknown
- 2019-09-16 MX MX2020007072A patent/MX2020007072A/es unknown
- 2019-09-16 DK DK19862449.6T patent/DK3715367T3/da active
- 2019-09-16 PT PT198624496T patent/PT3715367T/pt unknown
- 2019-09-16 ES ES19862449T patent/ES2985387T3/es active Active
- 2019-09-17 TW TW108133398A patent/TWI755630B/zh active
- 2019-09-17 TW TW110122590A patent/TWI824258B/zh active
-
2020
- 2020-06-17 ZA ZA2020/03645A patent/ZA202003645B/en unknown
- 2020-06-22 IL IL275592A patent/IL275592B/en unknown
- 2020-06-30 PH PH12020551026A patent/PH12020551026A1/en unknown
- 2020-07-14 CL CL2020001872A patent/CL2020001872A1/es unknown
-
2021
- 2021-01-05 KR KR1020210000775A patent/KR102558191B1/ko active Active
-
2022
- 2022-04-21 JP JP2022070213A patent/JP7569820B2/ja active Active
- 2022-08-01 US US17/878,664 patent/US12291555B2/en active Active
- 2022-08-01 US US17/878,703 patent/US12286464B2/en active Active
-
2025
- 2025-04-01 US US19/097,579 patent/US20250230212A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3715367T (pt) | Proteína de fusão compreendendo proteína il-2 e proteína cd80, e sua utilização | |
| IL279897A (en) | Fusosome compositions and uses thereof | |
| MA51291A (fr) | Protéines de fusion il-2 fc modifiées | |
| IL282225A (en) | Compositions and methods for immunotherapy | |
| EP3880814A4 (en) | FUSION PROTEIN | |
| DK3784283T3 (da) | Cannabidiopræparater og anvendelser deraf | |
| IL280317A (en) | Anti-avb8 antibodies and compositions and uses thereof | |
| EP3641762A4 (en) | N / O-LINKED DEGRONES AND DEGRONIMERS FOR PROTEIN DEGRADATION | |
| EP3820887A4 (en) | Pd1-4-1bbl variant fusion protein and methods of use thereof | |
| EP3633034A4 (en) | MODIFIED Cas9 PROTEIN AND USE THEREOF | |
| PT3494134T (pt) | Polipéptidos artificiais e sua utilização | |
| IL282178A (en) | Products, uses & methods | |
| EP3680331A4 (en) | MODIFIED CAS9 PROTEIN AND USE OF IT | |
| MA50908A (fr) | Formulations de protéines de fusion vegfr-fc | |
| EP3960756A4 (en) | FLAGELLIN FUSION PROTEIN AND USE THEREOF | |
| IL280631A (en) | Novel crispr-associated protein and use thereof | |
| EP3646887A4 (en) | CONJUGATE OF VEGF GRAB PROTEIN AND MEDICINAL PRODUCTS AND USES THEREOF | |
| DK3830120T5 (da) | Hidtil ukendt fusionsprotein specifikt for cd137 og pd-l1 | |
| DK3784047T3 (da) | Gærproteiner | |
| IL283644A (en) | Compositions and methods for immunotherapy | |
| EP3882277A4 (en) | FUSION PROTEIN AND USE THEREOF | |
| EP4083212A4 (en) | MUTANT RSV-F PROTEIN AND ITS USE | |
| EP3722305A4 (en) | HM-3 FUSION PROTEIN AND USES THEREOF | |
| EP3604343A4 (en) | FUSION PROTEIN, MANUFACTURING METHOD THEREFOR AND USE THEREOF | |
| EP3831945A4 (en) | PROTEIN HETERODIMER AND ITS USE |